Antidepressant Effect of a Dipeptide Brain-Derived-Neurotrophic-Factor Mimetic (GSB-106) in a Generic Oral Dosage Form

Resumo

A deficiency of brain-derived neurotrophic factor (BDNF) has now been demonstrated in many studies to play a central role in the pathogenesis of depression. The dimeric dipeptide BDNF-mimetic bis(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide or GSB-106 was discovered at Zakusov State Institute of Pharmacology. Previously, the antidepressant properties of GSB-106 at doses of 0.1 – 1 mg/kg i.p. were established in mice in the Porsolt forced swim test. An oral dosage form of GSB-106 was developed. The present research focused on the antidepressant activity of the GSB-106 dosage form in mice in the Porsolt forced swim test. It is established that GSB-106 in the oral dosage form possesses antidepressant activity for 14 d at doses of 0.05, 0.1, and 1 mg/kg.